Company Analysis

Coherus Oncology, Inc. (CHRS)

Nasdaq: CHRS · Biological Products, (No Diagnostic Substances) · Redwood City, CA · filing with the SEC since 2011
Grade4.8
◀ Past 3.5● Present 5.6▶ Future 5.0
1 est.

Who runs Coherus Oncology, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Lanfear Dennis M
President & CEO. First filing Nov 2014, latest Jun 2, 2026, 8 filings in all.
Officers reporting now
2
of 9 people with a filing in the last fifteen months
Directors reporting now
7
28 people on the record since 2014
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Lanfear Dennis MPresident & CEONov 2014Jun 2, 2026none
Mcmichael Bryan JChief Financial OfficerSep 2022Jun 2, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Karachun Rita AdirectorJun 2024Jun 9, 2026none
Newcomer Lee NisleydirectorFeb 2022Jun 9, 2026none
Newton Charles W.directorMay 2022Jun 9, 2026none
O'Donnell-Tormey JilldirectorMay 2022Jun 9, 2026none
Ryan Michael LeedirectorJul 2023Jun 9, 2026none
Satvat Ali J.directorNov 2014Jun 9, 2026none
Wahlstrom MatsdirectorNov 2014Jun 9, 2026none
Earlier names on the record24, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton CHRS · research, not advice